An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...

An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...

The disease entered Linda Adhiambo’s family in 2007 and never left. It has taken her mother, grandmother, aunt and cousins. Now, as she battles breast cancer, she asks: when will this cycle end?

In 2026, an estimated 158,850 new cases of colorectal cancer (CRC) will be diagnosed, and 55,230 people will die from the disease in the United States. The Alaska Native population has the highest CRC ...

Endometrial cancer (EC) incidence is rising globally, yet therapeutic progress has lagged behind other solid tumors, in part due to the complexity and ...

The presentations at ASCO GU signal a move toward more personalized, potent, and sequence-specific treatment strategies for genitourinary malignancies.

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

FDA approved Optune Pax for locally advanced pancreatic cancer with gemcitabine/nab-paclitaxel, marking the first new modality in decades for this nonresectable ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced breast cancer who received elacestrant plus everolimus or abemaciclib had “clinically ...